These findings are further supported by another sub-analysis of SURMOUNT1, which reported a 33.9% (8.2% for placebo) reduction in fat mass and a 10.9% (2.6% for placebo) reduction in lean mass by week 72, with approximately 75% of weight loss attributable to fat mass, consistent across clinically relevant subgroups [68]
At week 68, more participants in the semaglutide groups (semaglutide 2.4 mg, 1.7 mg) respectively than in the placebo group achieved weight reductions of 5% (82.9%, 72.4% vs
With time, this allows your system to burn excess fat and can even improve the health and activity of the pancreatic cells responsible for your insulin response
That means nearly all of it passes through you without doing anything
Clinical research Research by Khavinson et al
Through its dual-action mechanism, healthcare providers can streamline treatment protocols while delivering improved patient outcomes, with many endocrinology practices finding that these combinations ultimately minimize medication burden and maximize therapeutic effectiveness